Sorigue, M., Bishton, M., Domingo-Domenech, E., McMillan, A., Prusila, R., García, O., Kuusisto, M., Condom, M., Tapia, G., Ribera, J.-M., Kuittinen, O., Fox, C. P., & Sancho, J.-M. (2019). Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma. Leukemia & Lymphoma, 60(10), 2524-2531. https://doi.org/10.1080/10428194.2019.1594212